All In Biotech

Drug Trial Radar · NCT02603081

Study to Evaluate SPI-1005 in Adults With Meniere's Disease

Phase 1b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of SPI-1005 in Meniere's Disease

Last checked: Nov 19, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

40

Actual

Start

Dec 2015

Primary completion

Aug 2017

Study completion Aug 2017

Sponsor

Sponsor type
Industry
First posted
Nov 11, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 19 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and efficacy of three dose levels of SPI-1005 compared to placebo on vertigo, tinnitus and sensorineural hearing loss in 40 adults with Meniere's disease.

Conditions

  • Meniere's Disease

Interventions

  • SPI-1005Drug

    Ebselen is a small molecule mimic and inducer of glutathione peroxidase (GPx). GPx reduces reactive oxygen species by the binding of free radicals to its selenium moiety. Ebselen has strong anti-inflammatory characteristics.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of of Treatment-Emergent Adverse EventsTime frame: 7 weeks

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • House Clinic

    Los Angeles, California

  • New York Otology

    New York, New York

  • MUSC

    Charleston, South Carolina

  • Sound Pharmaceuticals, Inc.

    Seattle, Washington

  • Northwest Ear

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.